Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2017'; Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 21 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. 

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNF-receptor superfamily. This protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. 

The report 'Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2017' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 6, 4 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Hematological Disorders, Hormonal Disorders and Metabolic Disorders which include indications Solid Tumor, Crohn's Disease (Regional Enteritis), Kidney Transplant Rejection, Lymphoma, Melanoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Ovarian Cancer, Rheumatoid Arthritis, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Gastroesophageal (GE) Junction Carcinomas, Graves Diseases, Heart Transplant Rejection, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hyperthyroidism, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Lupus Nephritis, Membranous Glomerulonephritis, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Metastatic Ovarian Cancer, Multiple Sclerosis, Myasthenia Gravis, Osteosarcoma, Pancreatic Islet Transplant Rejection, Primary Biliary Cirrhosis, Prostate Cancer, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Overview 8
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Development 9
Products under Development by Stage of Development 9
Products under Development by Therapy Area 10
Products under Development by Indication 11
Products under Development by Companies 14
Products under Development by Universities/Institutes 19
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Assessment 21
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Companies Involved in Therapeutics Development 27
AbbVie Inc 27
Apexigen Inc 28
Apogenix GmbH 28
Boehringer Ingelheim GmbH 29
Bristol-Myers Squibb Company 29
Celldex Therapeutics Inc 30
Denceptor Therapeutics Ltd 30
F. Hoffmann-La Roche Ltd 31
Johnson & Johnson 32
Kyowa Hakko Kirin Co Ltd 33
Novartis AG 34
Seattle Genetics Inc 35
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Drug Profiles 36
2C-10 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ABBV-428 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
APG-1233 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
APX-005M - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
BI-655064 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Bispecific Monoclonal Antibody to Agonize CD40 for Oncology - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
bleselumab - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
BMS-986090 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
CDX-1140 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
CFZ-533 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
DNP-005 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
emactuzumab + RG-7876 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
FFP-104 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
JNJ-7107 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
KGYY-15 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Monoclonal Antibodies to Agonize CD40 and FCGR2B for B-cell Lymphoma and Melanoma - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Monoclonal Antibody Conjugate to Target CD40 for Pancreatic Cancer - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
RG-7876 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
RG-7876 + vanucizumab - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
SEA-CD40 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Dormant Products 63
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Discontinued Products 65
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Product Development Milestones 66
Featured News & Press Releases 66
Jul 17, 2017: Apexigen Announces First Patient Dosed in Phase 1b/2 Clinical Trial of APX005M in Combination with Opdivo (nivolumab) in Advanced Solid Tumors 66
May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ADC-1013 66
Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ADC-1013 at PEGS conference in Boston, May 4 67
Apr 03, 2017: Phase I Clinical Trial Completes Using Cell Line Expertise at Cobra Biologics 67
Mar 23, 2017: Alligator announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013 68
Mar 21, 2017: Phase 1/2 Clinical Trial of Apexigen's APX005M in Combination with Pembrolizumab (Keytruda) Opens for Metastatic Melanoma Patients 68
Dec 05, 2016: Celldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid Malignancies, at the American Society of Hematology Annual Meeting 69
Nov 14, 2016: Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody 69
Oct 12, 2016: Alligator Bioscience informs that dosing has started in a second clinical phase I study with the CD40 Agonistic Immuno-Oncology Antibody ADC-1013 70
Apr 22, 2016: Alligator Bioscience Recieves First Milestone Payment for ADC-1013 70
Apr 18, 2016: Seattle Genetics Highlights Data on SEA-CD40 at the American Association for Cancer Research Annual Meeting 71
Apr 13, 2016: Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences 71
Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn's Disease with anti-CD40 Monoclonal Antibody 72
Nov 17, 2015: Apexigen Presents Positive Data for APX005M in Podium Presentation at Immune Checkpoint Inhibitors (ICI) Europe 72
Nov 06, 2015: Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at SITC 2015 Meeting 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Therapy Areas, H2 2017 10
Number of Products under Development by Indications, H2 2017 11
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 13
Number of Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 15
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 18
Number of Products under Investigation by Universities/Institutes, H2 2017 19
Products under Investigation by Universities/Institutes, H2 2017 20
Number of Products by Stage and Mechanism of Actions, H2 2017 22
Number of Products by Stage and Route of Administration, H2 2017 24
Number of Products by Stage and Molecule Type, H2 2017 26
Pipeline by AbbVie Inc, H2 2017 27
Pipeline by Apexigen Inc, H2 2017 28
Pipeline by Apogenix GmbH, H2 2017 28
Pipeline by Boehringer Ingelheim GmbH, H2 2017 29
Pipeline by Bristol-Myers Squibb Company, H2 2017 29
Pipeline by Celldex Therapeutics Inc, H2 2017 30
Pipeline by Denceptor Therapeutics Ltd, H2 2017 30
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 31
Pipeline by Johnson & Johnson, H2 2017 32
Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 33
Pipeline by Novartis AG, H2 2017 34
Pipeline by Seattle Genetics Inc, H2 2017 35
Dormant Products, H2 2017 63
Dormant Products, H2 2017 (Contd..1), H2 2017 64
Discontinued Products, H2 2017 65